4D MOLECULAR THERAPEUTICS IN (FDMT)
US35104E1001 - Common Stock
4D MOLECULAR THERAPEUTICS IN
NASDAQ:FDMT (4/30/2024, 7:00:02 PM)
After market: 23.93 0 (0%)23.93
-0.32 (-1.32%)
Company Profile
4D Molecular Therapeutics, Inc. operates as a clinical stage biotherapeutics company, which engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. The company is headquartered in Emeryville, California and currently employs 144 full-time employees. The company went IPO on 2020-12-11. The firm is developing a diverse pipeline of product candidates for both large market and rare diseases, including patient populations that other genetic medicines are unable to address. The firm's initial product candidates are focused on therapeutic areas, such as ophthalmology, pulmonology, and cardiology. The firm's five product candidates include 4D-150, 4D-710, 4D-125, 4D-110, and 4D-310. 4D-150 is used for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). 4D-710 is used for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations). 4D-310 is used for the treatment of Fabry disease cardiomyopathy. 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP). 4D-110 is used for the treatment of choroideremia.
Company Info
4D MOLECULAR THERAPEUTICS IN
5858 Horton Street #455, Emeryville
Emeryville CALIFORNIA
P: 15105052680
Employees: 144
Website: https://4dmoleculartherapeutics.com/
FDMT News
a month ago - 4D Molecular Therapeutics, Inc.4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisConducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear...
2 months ago - 4D Molecular Therapeutics, Inc.4DMT to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic...
2 months ago - 4D Molecular Therapeutics, Inc.4DMT Reports Full Year 2023 Financial Results and Operational HighlightsPresented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease...
FDMT Twits
Here you can normally see the latest stock twits on FDMT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
